The Challenge in Burden of Pulmonary Arterial Hypertension: A Perspective From the Global Burden of Disease Study

Abstract

Pulmonary arterial hypertension (PAH) poses significant clinical management challenges due to gaps in understanding its global epidemiology. We analyzed PAH-related disability-adjusted life years (DALYs), deaths, and prevalence from 1990 to 2021. Age-period-cohort models and regression analyses assessed temporal trends and projected burdens to 2050. Globally, PAH-related DALYs declined by 6.6%, but increased by 13.9% in high socio-demographic index (SDI) countries. Middle SDI regions reported the highest DALYs in 1990 and 2021. Deaths rose by 48.5% worldwide, with high SDI nations experiencing a 76.6% surge. Age-standardized rates (ASRs) of DALYs and deaths decreased across SDI countries, with high-middle SDI regions showing the steepest declines. Younger age groups, especially males, had a higher proportion of global DALYs in earlier years, but the burden shifted toward older populations over time, with this trend more pronounced in high-SDI countries. Age-period-cohort analysis revealed declining DALYs in younger ages but rising rates in older cohorts. By 2050, deaths and prevalence are projected to rise, disproportionately affecting females. Significant regional disparities in PAH burden persist, necessitating targeted policies, improved healthcare access, and early detection strategies, especially in underserved areas. Addressing these disparities is critical for mitigating PAH’ s global impact.

Keywords

pulmonary arterial hypertension / global burden of disease study / disability-adjusted life years / death / prevalence / pediatric

References

[1] M. Humbert, G. Kovacs, M. M. Hoeper, et al., “2022 Esc/Ers Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension,” European Heart Journal 43, no. 38 (2022): 3618-3731.

[2] P. M. Hassoun, “Pulmonary Arterial Hypertension,” New England Journal of Medicine 385, no. 25 (2021): 2361-2376.

[3] A. Mocumbi, M. Humbert, A. Saxena, et al., “Pulmonary Hypertension,” Nature Reviews Disease Primers 10, no. 1 (2024): 1.

[4] G. E. D'Alonzo, R. J. Barst, S. M. Ayres, et al., “Survival in Patients With Primary Pulmonary Hypertension. Results From a National Prospective Registry,” Annals of Internal Medicine 115, no. 5 (1991): 343-349.

[5] H. W. Farber, D. P. Miller, A. D. Poms, et al., “Five-Year Outcomes of Patients Enrolled in the Reveal Registry,” Chest 148, no. 4 (2015): 1043-1054.

[6] A. Boucly, L. Savale, X. Jaïs, et al., “Association Between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension,” American Journal of Respiratory and Critical Care Medicine 204, no. 7 (2021): 842-854.

[7] “Global, Regional, and National Burden of Pulmonary Arterial Hypertension, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.” The Lancet Respiratory Medicine (2024).

[8] G. A. Mensah, V. Fuster, C. J. L. Murray, and G. A. Roth, “Global Burden of Cardiovascular Diseases and Risks, 1990-2022,” Journal of the American College of Cardiology 82, no. 25 (2023): 2350-2473.

[9] E. B. Rosenzweig, S. H. Abman, I. Adatia, et al., “Paediatric Pulmonary Arterial Hypertension: Updates on Definition, Classification, Diagnostics and Management,” European Respiratory Journal 53, no. 1 (2019): 1801916.

[10] Z. Su, Z. Zou, S. I. Hay, et al., “Global, Regional, and National Time Trends in Mortality for Congenital Heart Disease, 1990-2019: An Age-Period-Cohort Analysis for the Global Burden of Disease 2019 Study,” EClinicalMedicine 43 (2022): 101249.

[11] Y. Yang, F. Lin, Z. Xiao, et al., “Investigational Pharmacotherapy and Immunotherapy of Pulmonary Arterial Hypertension: An Update,” Biomedicine & Pharmacotherapy 129 (2020): 110355.

[12] B. A. Maron, S. H. Abman, C. G. Elliott, et al., “Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances,” American Journal of Respiratory and Critical Care Medicine 203, no. 12 (2021): 1472-1487.

[13] S. Johnson, N. Sommer, K. Cox-Flaherty, N. Weissmann, C. E. Ventetuolo, and B. A. Maron, “Pulmonary Hypertension: A Contemporary Review,” American Journal of Respiratory and Critical Care Medicine 208, no. 5 (2023): 528-548.

[14] I. Cuthbertson, N. W. Morrell, and P. Caruso, “Bmpr2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension,” Circulation Research 132, no. 1 (2023): 109-126.

[15] D. E. van der Feen, B. Bartelds, R. A. de Boer, and R. M. F. Berger, “Pulmonary Arterial Hypertension in Congenital Heart Disease: Translational Opportunities to Study the Reversibility of Pulmonary Vascular Disease,” European Heart Journal 38, no. 26 (2017): 2034-2041.

[16] B. Thoreau and L. Mouthon, “Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases (Ctd-Pah): Recent and Advanced Data,” Autoimmunity Reviews 23, no. 4 (2024): 103506.

[17] Y. Yang, H. Zhang, Y. Wang, et al., “Promising Dawn in the Management of Pulmonary Hypertension: The Mystery Veil of Gut Microbiota,” Imeta 3, no. 2 (2024): e159.

[18] E. von Romberg, “Über Sklerose Der Lungenarterie,” Deutsches Archiv Fur Klinische Medizin 48 (1891): 197-206.

[19] R. J. Barst, “Pulmonary Hypertension: Past, Present and Future,” Annals of Thoracic Medicine 3, no. 1 (2008): 1-4.

[20] D. S. O'Callaghan, L. Savale, D. Montani, et al., “Treatment of Pulmonary Arterial Hypertension With Targeted Therapies,” Nature Reviews Cardiology 8, no. 9 (2011): 526-538.

[21] M. M. Hoeper, M. Humbert, R. Souza, et al., “A Global View of Pulmonary Hypertension,” The Lancet Respiratory Medicine 4, no. 4 (2016): 306-322.

[22] E. M. T. Lau, E. Giannoulatou, D. S. Celermajer, and M. Humbert, “Epidemiology and Treatment of Pulmonary Arterial Hypertension,” Nature Reviews Cardiology 14 (2017): 603-614.

[23] S. Rich, D. R. Dantzker, S. M. Ayres, et al., “Primary Pulmonary Hypertension. A National Prospective Study,” Annals of Internal Medicine 107, no. 2 (1987): 216-223.

[24] M. D. McGoon, R. L. Benza, P. Escribano-Subias, et al., “Pulmonary Arterial Hypertension: Epidemiology and Registries,” Journal of the American College of Cardiology 62, no. 25 Suppl (2013): D51-D59.

[25] M. M. Hoeper and R. G. J. Simon, “The Changing Landscape of Pulmonary Arterial Hypertension and Implications for Patient Care,” European Respiratory Review 23, no. 134 (2014): 450-457.

[26] A. Foderaro and C. E. Ventetuolo, “Pulmonary Arterial Hypertension and the Sex Hormone Paradox,” Current Hypertension Reports 18, no. 11 (2016): 84.

[27] S. Umar, M. Rabinovitch, and M. Eghbali, “Estrogen Paradox in Pulmonary Hypertension: Current Controversies and Future Perspectives,” American Journal of Respiratory and Critical Care Medicine 186, no. 2 (2012): 125-131.

[28] C. L. Welch and W. K. Chung, “Genetics and Other Omics in Pediatric Pulmonary Arterial Hypertension,” Chest 157, no. 5 (2020): 1287-1295.

[29] Z. Bai, J. Han, J. An, et al., “The Global, Regional, and National Patterns of Change in the Burden of Congenital Birth Defects, 1990-2021: An Analysis of the Global Burden of Disease Study 2021 and Forecast to 2040,” EClinicalMedicine 77 (2024): 102873.

[30] D. D. Ivy, S. H. Abman, R. J. Barst, et al., “Pediatric Pulmonary Hypertension,” Journal of the American College of Cardiology 62, no. 25 Suppl (2013): D117-D126.

[31] A. Constantine, K. Dimopoulos, S. G. Haworth, V. Muthurangu, and S. Moledina, “Twenty-Year Experience and Outcomes in a National Pediatric Pulmonary Hypertension Service,” American Journal of Respiratory and Critical Care Medicine 206, no. 6 (2022): 758-766.

[32] R. J. Barst, S. I. Ertel, M. Beghetti, and D. D. Ivy, “Pulmonary Arterial Hypertension: A Comparison Between Children and Adults,” European Respiratory Journal 37, no. 3 (2011): 665-677.

[33] China Specialty Alliance for Pulmonary Hypertension. National Center For Cardiovascular Diseases. Accessed March 3, 2025, https://csaph.nccd.org.cn/Home.

[34] A. R. Maligireddy, S. Shore, A. Sreenivas Kumar, et al., “Current Status and Barriers in Pulmonary Hypertension Care Delivery in India: A Qualitative Analysis,” Pulmonary Circulation 12, no. 2 (2022): e12094.

[35] A. P. Fishman, “A Century of Pulmonary Hemodynamics,” American Journal of Respiratory and Critical Care Medicine 170, no. 2 (2004): 109-113.

[36] A. Liu, G. P. Diller, P. Moons, C. J. Daniels, K. J. Jenkins, and A. Marelli, “Changing Epidemiology of Congenital Heart Disease: Effect on Outcomes and Quality of Care in Adults,” Nature Reviews Cardiology 20, no. 2 (2023): 126-137.

[37] A. Finckh, B. Gilbert, B. Hodkinson, et al., “Global Epidemiology of Rheumatoid Arthritis,” Nature Reviews Rheumatology 18, no. 10 (2022): 591-602.

[38] O. Adelowo, G. M. Mody, M. Tikly, O. Oyoo, and S. Slimani, “Rheumatic Diseases in Africa,” Nature Reviews Rheumatology 17, no. 6 (2021): 363-374.

[39] Schistosomiasis (Bilharzia). World Health Organization. Accessed March 3, 2025, https://www.who.int/health-topics/schistosomiasis#tab=tab_1.

[40] S. Wu, J. Wang, Q. Guo, et al., “Prevalence of Human Immunodeficiency Virus, Syphilis, and Hepatitis B and C Virus Infections in Pregnant Women: A Systematic Review and Meta-Analysis,” Clinical Microbiology and Infection 29, no. 8 (2023): 1000-1007.

[41] GBD 2021 Diseases and Injuries Collaborators. “Global Incidence, Prevalence, Years Lived With Disability (Ylds), Disability-Adjusted Life-Years (Dalys), and Healthy Life Expectancy (Hale) for 371 Diseases and Injuries in 204 Countries and Territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.” Lancet 403, no. 10440 (2024): 2133-2161.

[42] C. J. Murray and A. D. Lopez, “Global Mortality, Disability, and the Contribution of Risk Factors: Global Burden of Disease Study,” Lancet 349 (1997): 1436-1442.

[43] GBD 2019 Risk Factors Collaborators. “Global Burden of 87 Risk Factors in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019.” Lancet 396, no. 10258 (2020): 1223-1249.

[44] Pulmonary arterial hypertension. Institute For Health Metrics and Evaluation. Accessed March 3, 2025, https://www.healthdata.org/sites/default/files/methods_appendices/2021/Emmons-Bell_PAH_GBD2021_07212023_AC.pdf.

[45] GBD 2019 Mental Disorders Collaborators. “Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019.” Lancet Psychiatry 9, no. 2 (2022): 137-150.

[46] GBD 2019 Adolescent Mortality Collaborators. “Global, Regional, and National Mortality Among Young People Aged 10-24 Years, 1950-2019: A Systematic Analysis for the Global Burden of Disease Study 2019.” Lancet 398, no. 10311 (2021): 1593-1618.

[47] Global Burden of Disease Study 2021 Socio-Demographic Index. Institute For Health Metrics and Evaluation. Accessed March 3, 2025, https://ghdx.healthdata.org/record/global-burden-disease-study-2021-gbd-2021-socio-demographic-index-sdi-1950%E2%80%932021.

[48] GBD 2019 Human Resources for Health Collaborators. “Measuring the Availability of Human Resources for Health and Its Relationship to Universal Health Coverage for 204 Countries and Territories From 1990 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.” Lancet 399, no. 10341 (2022): 2129-2154.

[49] Y. Zheng, Q. Yu, Y. Lin, et al., “Global Burden and Trends of Sexually Transmitted Infections From 1990 to 2019: An Observational Trend Study,” The Lancet Infectious Diseases 22, no. 4 (2022): 541-551.

[50] P. S. Rosenberg and W. F. Anderson, “Age-Period-Cohort Models in Cancer Surveillance Research: Ready for Prime Time?,” Cancer Epidemiology and Prevention Biomarkers 20, no. 7 (2011): 1263-1268.

[51] P. S. Rosenberg and W. F. Anderson, “Proportional Hazards Models and Age-Period-Cohort Analysis of Cancer Rates,” Statistics in Medicine 29, no. 11 (2010): 1228-1238.

[52] S. Shu, Y. Yang, B. Sun, et al., “Alerting Trends in Epidemiology for Calcific Aortic Valve Disease, 1990-2019: An Age-Period-Cohort Analysis for the Global Burden of Disease Study 2019,” European Heart Journal - Quality of Care and Clinical Outcomes 9, no. 5 (2023): 459-473.

[53] Z. Zou, G. Liu, S. I. Hay, et al., “Time Trends in Tuberculosis Mortality Across the Brics: An Age-Period-Cohort Analysis for the Gbd 2019,” EClinicalMedicine 53 (2022): 101646.

[54] Z. Zou, K. Cini, B. Dong, et al., “Time Trends in Cardiovascular Disease Mortality Across the Brics: An Age-Period-Cohort Analysis of Key Nations With Emerging Economies Using the Global Burden of Disease Study 2017,” Circulation 141, no. 10 (2020): 790-799.

[55] GBD 2019 Hearing Loss Collaborators, “Hearing Loss Prevalence and Years Lived With Disability, 1990-2019: Findings From the Global Burden of Disease Study 2019.” Lancet 397, no. 10278 (2021): 996-1009.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.